CRITICAL
NEED
Problem
Critical shortage of medical isotopes for cancer diagnostics & therapies — 95%+ imported.
Solution
Eden’s proprietary platform — purpose-built, low-energy, high-output facilities in North America
Advantage
10-year, and >$50M of non-dilutive capital head start, DOE-validated tech and first-mover U.S. licensing.
Isotope Shortages Threaten Patient Care and Medical Innovation
New radioactive isotope therapies promise more targeted attacks on cancer — but they’re in such demand that shortages recently stalled a promising clinical trial.
-Science, 2025
- The DOE managed/funded the Medical Isotope Program in the 1990s. Under this program, Sandia National Laboratories's nuclear facilities were to become a backup supplier and produce greater than 50% of U.S. demand for Mo-99 at the time.
- Despite Sandia’s significant progress towards this goal (estimated at 80% complete), DOE ended the program in 1998 under a false forecast that anticipated Canadian production.
- Scaled Canadian production did not materialize and by 2018 halted. Shortages of isotopes led to delays/cancellations in diagnostic tests for patients.
- In 2012, Congress passed the American Medical Isotopes Production Act to establish a domestic supply of Mo-99 using LEU. Several companies have proposed different methods for Mo-99 production, yet none have succeeded to date.
- Supply chain uncertainty of Mo-99 continues and there is limited global Lu-177 production capacity.
RISING CANCER RATES
The Healthcare Crisis
Cancer is the second leading cause of death worldwide
#
0
New cancer diagnoses in the U.S. every year
0
M+
deaths in the U.S. annually
0
K+
Global incidence of new cancer cases of all types are projected to significantly increase in the next 15 years due to aging populations and expanded screening efforts.